Ann: Voluntary Suspension, page-64

First 64 Last

Share
Profile

Follow
Hasty78

261 Posts.

49

07/02/19

13:39

Post #: 37363247
Share

Originally posted by aniesbaswedan: ↑

If you ever bothered to read what I posted then you would realize that I elaborated on everything in detail. Some of what I said:

Ever since the SP was around 20 cents...

That the beeptool agreement was silly...

That the 3Ds were never going to make any significant revenue...

That there was going to be CR at 12 cents and warned everyone about it.

That the SP was going to go way below 12 cents and I warned everyone about it.

That the CR amount was never going to be enough for what it was meant to be for. That there was going to be another CR relatively soon.

Warned about pumps in the share price fluctuation.

Then I warned everyone that there was going to be another CR at around 4.1 cents before end of February.

Those are just some of the things I have said...everything came true and yet everytime I uttered each of the aforementioned predictions I was trolled...

Broken clock? If I am broken then what about those people who was so adamant that there was going to be billionaire investor, self sustaining 3Ds revenue of millions, no CR, etc?

A lot of the people here have made their beds and now sleeping on it. Their choice and they made their choice aware of all the warnings and risks.

Expand

Oh we know you elaborate everything. thing is we get good news you vanish and when its quite for a week you start in again. you've predicted a falling share price mid-fall in the middle of Americas trade war when the whole market was down.

SAS Price at posting: 5.4¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

AI stocks: What to expect in 2024-25

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability